{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:18Z","timestamp":1787238858946,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.canrad.2019.07.157","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T08:16:03Z","timestamp":1566980163000},"page":"662-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Combination of chemotherapy and radiotherapy: A thirty years evolution"],"prefix":"10.1016","volume":"23","author":[{"given":"C.","family":"Hennequin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Quero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.07.157_bib0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0360-3016(79)90044-0","article-title":"Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity","volume":"5","author":"Steel","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.157_bib0235","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ijrobp.2005.06.023","article-title":"Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis","volume":"64","author":"Sasse","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.157_bib0240","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0959-8049(01)00360-4","article-title":"Biological basis for chemo-radiotherapy interactions","volume":"38","author":"Hennequin","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2019.07.157_bib0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm--general principles","volume":"4","author":"Seiwert","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semradonc.2005.08.001","article-title":"Biologic basis for combining drugs with radiation","volume":"16","author":"Wilson","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0255","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0260","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","article-title":"Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial","volume":"88","author":"Dillman","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2019.07.157_bib0265","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0360-3016(97)00365-9","article-title":"Induction cisplatin\/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08\/ECOG 4588","volume":"39","author":"Komaki","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.157_bib0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jnci\/83.6.417","article-title":"Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients","volume":"83","author":"Le Chevallier","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2019.07.157_bib0275","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.2591","article-title":"Induction Chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 Phase III Randomized Trial","author":"Geoffrois","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0285","doi-asserted-by":"crossref","first-page":"e6165","DOI":"10.1097\/MD.0000000000006165","article-title":"The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: a systematic review and meta-analysis","volume":"96","author":"Luo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.canrad.2019.07.157_bib0290","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199408253310803","article-title":"Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery","volume":"331","author":"O\u2019Connell","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.07.157_bib0295","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0300","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: mechanism of action and related DNA repair systems","volume":"56","author":"Marchesi","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.canrad.2019.07.157_bib0305","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.07.157_bib0310","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.07.157_bib0315","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0320","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-319-55231-6_13","article-title":"Tumor oxygenation status: facts and fallacies","volume":"977","author":"Vaupel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0325","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(05)70292-8","article-title":"Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial","volume":"6","author":"Overgaard","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0330","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","article-title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study","volume":"32","author":"DiSilvestro","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0335","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0340","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.05.005","article-title":"Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck","volume":"103","author":"Curtis","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0345","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q","article-title":"Molecular mechanisms of radiation-induced accelerated repopulation","volume":"7","author":"Schmidt-Ullrich","year":"1999","journal-title":"Radiat Oncol Investig"},{"key":"10.1016\/j.canrad.2019.07.157_bib0350","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2005.06.032","article-title":"Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation","volume":"76","author":"Krause","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0355","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2007.04.006","article-title":"EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms","volume":"83","author":"Baumann","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0365","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0375","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","article-title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Mesia","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.2518","article-title":"Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial","author":"Tao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0385","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.07.157_bib0390","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0395","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.157_bib0400","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canrad.2018.05.002","article-title":"Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma","volume":"23","author":"Quero","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.157_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20150582","article-title":"How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability","volume":"471","author":"Jeggo","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.canrad.2019.07.157_bib0410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.semradonc.2010.06.001","article-title":"Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets","volume":"20","author":"Chalmers","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.canrad.2019.07.157_bib0420","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/cns.12.13","article-title":"The potential of PARP inhibitors in neuro-oncology","volume":"1","author":"Carruthers","year":"2012","journal-title":"CNS Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0425","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final Report of a Phase I Trial of Olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2019.07.157_bib0430","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0435","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-14-1552","article-title":"A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis","volume":"21","author":"Reiss","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2019.07.157_bib0440","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.radonc.2015.03.028","article-title":"Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells","volume":"116","author":"Verhagen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.157_bib0445","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.18632\/oncotarget.6947","article-title":"PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response","volume":"7","author":"Wurster","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2019.07.157_bib0450","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2012.05.019","article-title":"The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective","volume":"84","author":"Ataman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:31:33Z","timestamp":1761136293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819303336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":45,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1278321819303336"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.157","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of chemotherapy and radiotherapy: A thirty years evolution","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}